ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2122

Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis

Jaspreet Bahia1, Christian Steppe2, Hannah Brubeck3, Radhika Narla2, George Mount4, Elizabeth Wahl5 and Katherine Wysham6, 1University of Washington, SEATTLE, WA, 2VA Puget Sound Healthcare System, Seattle, WA, Seattle, WA, 3VA Puget Sound Health Care System, Seattle, WA, 4Madigan Army Medical Center, Lakewood, WA, 5VA Puget Sound Healthcare System, Seattle, WA, 6VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA

Meeting: ACR Convergence 2024

Keywords: osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Glucocorticoid induced osteoporosis (GIOP) accelerates bone loss and increases fracture risk. We evaluated GIOP screening and prescribing patterns in our Veterans Affairs (VA)-based academic rheumatology clinic. Our quality improvement work focused on 1) prescription of supplemental calcium and vitamin D, 2) dual-energy x-ray absorptiometry (DXA) scan ordering, 3) FRAX risk stratification and assessment of appropriate osteoporosis (OP) medication prescribing including oral or IV bisphosphonate, PTH-analogues, denosumab, or romosozumab.

Methods: Veterans on chronic GC (≥2.5mg prednisone, ≥ 3 months) with an active prescription from a rheumatology provider were extracted in a data pull on 3/14/24. Prescription data for supplemental calcium, vitamin D (Ca/D), and OP medication were also included. GC dose and duration, calcium intake, DXA scans, left femoral-neck T score (LFNTS) were recorded and manually validated, including data through 6/1/24. FRAX scores were calculated for each patient using the University of Sheffield FRAX calculator. FRAX score for major osteoporotic fracture (MOF) and hip fracture risk was increased by 15% and 20% for GC use >7.5mg/day per ACR guidelines. Patients were risk-stratified as very high (LFNTS ≤-3.5 or FRAX 10 yr risk of MOF and hip fracture of ≥30% and ≥4.5% respectively), high (LFNTS ≤-2.5 or FRAX 10 yr risk of MOF and hip fracture of ≥20% and ≥3% respectively), moderate (FRAX 10 yr risk of MOF and hip fracture of 10-20% and 1-3% respectively) or low risk (FRAX 10 yr risk of MOF and hip OP fracture of < 10% and < 1% respectively). For patients without recent DXA, clinical FRAX data were calculated without BMD. We recorded rates of Ca/D prescription, DXA test completion, and OP medication utilization based on FRAX risk category.

Results: Forty-five patients were included in the data pull. Of 45, twenty-six (58%) were prescribed Ca/D. Twenty-six (58%) had DXA within 2 years and 19 (42%) did not. Of those with a recent DXA, FRAX calculations resulted in classifying 2 patients as very high risk, 13 as high risk, 2 as moderate risk, and 9 as low risk. Of the 17 moderate to very high-risk patients, 15 (88%) were on OP therapy; of the two who were not, one had an expired prescription and one declined treatment. Of the 19 patients without recent DXA, 10 had never had DXA, 3 had testing >5 years prior, and 4 were on GC without updated imaging. Clinical FRAX was calculated in patients without DXA (except 1 who was < 40 years). Of these, one was very high risk, 8 (42%) were high risk, 7 (36%) were moderate risk, and two were low risk; none were on OP therapy.

Conclusion: In our VA-based academic rheumatology practice, veterans on chronic GC do not consistently receive Ca/D supplementation and are under-screened according to the 2022 GIOP guideline, though patients with DXA testing are appropriately treated. Clinical FRAX should be considered in patients without recent DXA. Developing population health tools to improve monitoring in this population remains challenging as many data domains in GIOP care require chart validation (true GC use vs. taper, over-the-counter calcium use, risk factors, DXA results) or calculation (FRAX).   

Supporting image 1

Figure 1: Local quality gaps in GIOP care and targets for improvement

Supporting image 2


Disclosures: J. Bahia: Eli Lilly, 12, Stock ownership; C. Steppe: None; H. Brubeck: None; R. Narla: None; G. Mount: None; E. Wahl: None; K. Wysham: None.

To cite this abstract in AMA style:

Bahia J, Steppe C, Brubeck H, Narla R, Mount G, Wahl E, Wysham K. Rheum for Improvement: Screening and Treatment of Glucocorticoid Induced Osteoporosis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/rheum-for-improvement-screening-and-treatment-of-glucocorticoid-induced-osteoporosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheum-for-improvement-screening-and-treatment-of-glucocorticoid-induced-osteoporosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology